Why I’m watching the Centrica share price closely now

Centrica’s share price is rising finally, but is it reason to buy?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

RISK WARNING: should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice. The Motley Fool believes in building wealth through long-term investing and so we do not promote or encourage high-risk activities including day trading, CFDs, spread betting, cryptocurrencies, and forex. Where we promote an affiliate partner’s brokerage products, these are focused on the trading of readily releasable securities.

The Centrica (LSE: CNA) share price had a good run this past week, breaking past the 80p mark for the first time in four months after it released a somewhat upbeat trading update. This is very good news for the FTSE 100 share, which has been struggling for a while.

But I believe that it will take more than a single trading update to lift the share price meaningfully, especially after seeing how much it has fallen over the years. To put it in context, the CNA share price has lost over half its value from five years ago. It’s also at a fraction of the highs it has seen over the decade.

No capital gains here

The loss in value was one of my biggest concerns when I first wrote about CNA in May this year. For investors like me, who invest for capital gains, Centrica’s trend isn’t comforting at all. It is one of the reasons why I decided at the time that it was a better idea to hold off from investing in CNA and put it on my ‘wait and watch’ list instead.

Make no mistake, this latest spike in price is a movement in the right direction for the energy supplier. Nevertheless, the share price is a whole 13% lower than when I first talked about it.

Certainly, I wouldn’t buy Centrica shares right now, and I won’t until it has shown some consistent upward price movements. The key question is, to my mind, whether to even keep it on the ‘wait and watch’ list. To me, that depends on how it’s performing right now and how it’s expected to perform going forward.

Promise of better times

The latest trading update contains a few positives about the business, like growth in total customer accounts, higher margins and…. acceleration of cost efficiency delivery”. It also reports that CNA is on track to achieve full-year targets. A case to made for the stock, if a good dividend yield makes you tick. For me, Centrica is still on my ‘wait and watch’ list.

But while we are waiting and watching, may I suggest some shares that are far more predictable in their share price trajectory? Unilever is one I like, because it has given huge capital gains in the past. It’s also a defensive share, being in the business of consumer staples. I have been focusing on this segment in the past days as macroeconomic uncertainty persists.

With its big presence across international markets, Brexit (or the more-likely Brexit limbo) isn’t about to rock its fortunes. Unilever’s share price has also fallen in November so far, making now a good time to invest in this high-quality share.

RISK WARNING: should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice. The Motley Fool believes in building wealth through long-term investing and so we do not promote or encourage high-risk activities including day trading, CFDs, spread betting, cryptocurrencies, and forex. Where we promote an affiliate partner’s brokerage products, these are focused on the trading of readily releasable securities.

Manika Premsingh has no position in any of the shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Publish Test

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut…

Read more »

Investing Articles

JP P-Press Update Test

Read more »

Investing Articles

JP Test as Author

Test content.

Read more »

Investing Articles

KM Test Post 2

Read more »

Investing Articles

JP Test PP Status

Test content. Test headline

Read more »

Investing Articles

KM Test Post

This is my content.

Read more »

Investing Articles

JP Tag Test

Read more »

Investing Articles

Testing testing one two three

Sample paragraph here, testing, test duplicate

Read more »